CSIMarket
 
Marinus Pharmaceuticals Inc   (MRNS)
Other Ticker:  
 
 
Price: $9.0200 $-0.37 -3.940%
Day's High: $9.69 Week Perf: -2.8 %
Day's Low: $ 8.84 30 Day Perf: -9.8 %
Volume (M): 395 52 Wk High: $ 11.26
Volume (M$): $ 3,566 52 Wk Avg: $8.42
Open: $9.40 52 Wk Low: $5.57



 Market Capitalization (Millions $) 486
 Shares Outstanding (Millions) 54
 Employees -
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -132
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics to treat various neurological disorders. The company specializes in developing drugs that modulate GABA receptors in the brain. These receptors play a crucial role in regulating neuronal activity and are involved in several neurological conditions.

Marinus Pharmaceuticals has developed Ganaxolone, a synthetic form of a naturally occurring neuroactive steroid called allopregnanolone. Ganaxolone acts on GABA receptors and has the potential to treat a range of CNS disorders, including epilepsy and postpartum depression.

The company is conducting clinical trials to evaluate the safety and efficacy of Ganaxolone in various conditions, including focal-onset seizures, status epilepticus, and fragile X syndrome. Marinus Pharmaceuticals is also exploring the potential use of Ganaxolone in other therapeutic areas such as neuropathic pain and behavioral disorders.

Overall, Marinus Pharmaceuticals Inc is focused on developing novel treatments for neurological disorders by leveraging its expertise in GABA receptor modulation and neuroactive steroids.


   Company Address: 5 Radnor Corporate Center, Suite 500 Radnor 19087 PA
   Company Phone Number: 801-4670   Stock Exchange / Ticker: NASDAQ MRNS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc Surges with 213.59% Revenue Growth in Q3 2023, Outshining Competitors

MRNS, a leading player in the Major Pharmaceutical Preparations sector, has made some remarkable strides in the stock market recently. In the third quarter of 2023, the company experienced a staggering revenue growth of 213.59%, reaching an impressive $7.34 million. This substantial increase in revenue has set MRNS apart from its sector contemporaries, as the overall sector only managed a revenue growth rate of 1.86% during the same period.
While MRNS flourished in terms of revenue, it did experience a deficit of $-0.61. However, this setback did not overshadow the company's overall performance. In fact, MRNS showed tremendous improvement compared to the prior reporting period, where its deficit was higher at $-0.61 per share. Additionally, the company's revenue saw a significant boost of 20.671%, rising from $6.08 million.

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc. Surges with Impressive 239.721% Revenue Growth in Q2 2023



Marinus Pharmaceuticals Inc, a pharmaceutical company specializing in the development of innovative therapies, recently released its financial results for the April to June 30, 2023 fiscal time-frame. The results showcased significant improvements across multiple key indicators, raising anticipation and optimism for the company's future prospects.
Improvement in Earnings Per Share (EPS):
One of the most encouraging aspects of the financial results is the improvement in Marinus Pharmaceuticals Inc's EPS. The company decreased its loss per share to $-0.61, a substantial improvement from $-1.06 reported in the same period the previous year. In addition, the EPS has progressed positively from -$0.67 when compared to the preceding reporting season. This improvement in EPS reflects a stronger financial position and suggests a potential positive trend for the company's profitability.

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc Faces Challenges in Account Receivable Collections, But Maintains Positive Receivables Turnover Ratio

Marinus Pharmaceuticals Inc is facing tougher challenges in its accounts receivable collections as indicated by the sequential worsening of its collection ratio to 3.55 in the Mar 31 2023 quarter. However, despite the increase in its average receivable collection period to 103 days, Marinus Pharmaceuticals Inc has managed to improve its overall receivables turnover ratio ranking to 414. While other healthcare sector companies have higher receivables turnover ratios, these figures still do not raise any cause for concern.
Unfortunately, Marinus Pharmaceuticals Inc has reported a growth in losses for the first quarter of 2023 due to weak business performance. This is evident in the financial report, where the net loss per share has edged up to $-0.67 from $-0.52, while revenue dropped by 26.829% from $14.19 million a year ago to $10.38 million. However, it is important to note that revenue surged by 44.932% from $7.16 million in Q4. Additionally, earnings per share also improved from $-0.72 to $-0.67 per share.






 

Marinus Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com